CARISOPRODOL AND ASPIRIN

Post-LOE

aspirin; carisoprodol

Oxford Drug Design
ANDAORALTABLET
Approved
Dec 1997
Lifecycle
Post-LOE
Competitive Pressure
30/100

Mechanism of Action

CLINICAL PHARMACOLOGY Carisoprodol: Carisoprodol is a centrally-acting muscle relaxant that does not directly relax tense skeletal muscles in man. The mode of action of carisoprodol in relieving acute muscle spasm of local origin has not been clearly identified, but may be related to its sedative…

Company
Oxford Drug Design
Oxford Drug Design
UK - Oxford
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.